Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

539
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Antigen-specific type 1 regulatory T cell responses shape immunity and disease tolerance in human malaria.

The Journal of clinical investigation·2026
Same author

Bacterial engineering for cancer therapy.

Nature cancer·2026
Same author

Temperate phages enhance bacterial host fitness via RNA-guided flagellar remodelling.

Nature microbiology·2026
Same author

Characteristic and endovascular management of peripancreatic arterial aneurysms: Experience from a single-center cohort study.

Science progress·2026
Same author

Engineered probiotics for tumor-targeted combination chemoimmunotherapy.

bioRxiv : the preprint server for biology·2026
Same author

pH-responsive polymeric-peptide complex enhances tumor immunogenic cell death by membrane disruption.

Journal of controlled release : official journal of the Controlled Release Society·2026

相关实验视频

Updated: Jul 13, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

940

针对固体瘤的益生菌引导的CAR-T细胞

Rosa L Vincent1, Candice R Gurbatri1, Fangda Li2

  • 1Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA.

Science (New York, N.Y.)
|October 12, 2023
PubMed
概括

工程细菌为瘤提供合成点,引导仿真抗原受体 (CAR) - T细胞杀死抗原无关的癌细胞. 在临床前的癌症模型中,这种益生菌导向的CAR-T细胞疗法 (ProCAR) 是有前途的.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.4K

相关实验视频

Last Updated: Jul 13, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

940
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.4K

科学领域:

  • 癌症学
  • 微生物学
  • 免疫疗法

背景情况:

  • 针对固体瘤的治疗因瘤异质性和缺乏特定抗原而面临挑战.
  • 细菌可以选择性地殖民瘤,并作为工程治疗交付平台.

研究的目的:

  • 开发一种结合益生菌和CAR-T细胞用于向癌症治疗的新平台.
  • 在固体瘤中克服抗原特异向的局限性.

主要方法:

  • 为了释放合成瘤目标,
  • 开发了益生菌引导的CAR-T细胞 (ProCARs) 用于在位瘤标记和溶解.
  • 在人类和小鼠癌症的异种移植和同源模型中测试了ProCARs.
  • 合成的益生菌可同时释放化学基因, 增强CAR-T细胞的招募能力.

主要成果:

  • ProCARs证明了CAR- T细胞的激活和抗原无关的瘤细胞溶解.
  • 该系统在多种临床前癌症模型中安全有效.
  • 多功能益生菌增强了CAR- T细胞的招募和治疗反应.

结论:

  • 益生菌引导的CAR-T细胞提供了针对固体瘤的可行策略.
  • 这种方法可以杀死抗原独立的癌细胞,并增强免疫疗法.
  • 进一步开发工程益生菌可以改善基于CAR-T细胞的癌症疗法.